ZICCUM AB submits patent application for thermostable dry-powder formulations of VLP-based vaccines (Virus-Like Particles)

Ziccum’s new patent application centers on using its unique drying technology, LaminarPace, to prepare new formulations of VLP-based vaccines that do not require today’s cold chain conditions to be transported. Approved VLP-based vaccines currently on the market against HPV (human papilloma virus, which causes cervical cancer), are Cervarix and Gardasil.Ziccum’s dry-powder formulation technology, LaminarPace, formulates vaccines that can meet, and surpass, WHO’s CTC (Cold Temperature Chain) requirements for vaccines, set at +40 degrees C. This unique formulation method could lead to a